Involvement of TLR3-Dependent PGES Expression in Immunosuppression by Human Bone Marrow Mesenchymal Stem Cells

Stem Cell Reviews and Reports

Volumn 14, Issue 2, 2018, Pages 286-293

  Kim, Dae Seong ^a,b   Lee, Whi Hyeong ^c   Lee, Myoung Woo ^a,b   Park, Hyun Jin ^a,b   Jang, In Keun ^d   Lee, Ji Won ^a   Sung, Ki Woong ^a   Koo, Hong Hoe ^a,b,e   Yoo, Keon Hee ^a,b,e  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Samsung Medical Center   (South Korea)

^c Korea University   (South Korea)

^d Biomedical Research Institute   (South Korea)

^e Sungkyunkwan University   (South Korea)

Author keywords

Cyclooxygenase 2; Immunosuppression; Mesenchymal stem cell; Prostaglandin E synthase; Prostaglandin E2

Indexed keywords

CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2; GAMMA INTERFERON; PROSTAGLANDIN E2; SMALL INTERFERING RNA; TOLL LIKE RECEPTOR 3; TUMOR NECROSIS FACTOR; PROSTAGLANDIN E SYNTHASE; TLR3 PROTEIN, HUMAN;

ARTICLE; BONE MARROW DERIVED MESENCHYMAL STEM CELL; BONE MARROW DERIVED MONONUCLEAR CELL; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETIC TRANSFECTION; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE; UPREGULATION; CELL CULTURE; GENETICS; MESENCHYMAL STEM CELL; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION;

CELL PROLIFERATION; CELLS, CULTURED; CYCLOOXYGENASE 2; DINOPROSTONE; HUMANS; IMMUNOSUPPRESSION; MESENCHYMAL STEM CELLS; PROSTAGLANDIN-E SYNTHASES; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 3;

EID: 85038883223     PISSN: 15508943     EISSN: 15586804     Source Type: Journal    
DOI: 10.1007/s12015-017-9793-6     Document Type: Article

References (31)

1. Ringden, O., Uzunel, M., Rasmusson, I., Remberger, M., Sundberg, B., Lonnies, H., et al. (2006). Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation, 81(10), 1390–1397.
2. Ruan, G. P., Yao, X., Liu, J. F., He, J., Li, Z. A., Yang, J. Y., et al. (2016). Establishing a tree shrew model of systemic lupus erythematosus and cell transplantation treatment. Stem Cell Research & Therapy, 7(1), 121.
3. Abdi, R., Fiorina, P., Adra, C., Atkinson, N., M., & Sayegh, M. H. (2008). Immunomodulation by mesenchymal stem cells: a potential therapeutic strategy for type 1 diabetes. Diabetes, 57(7), 1759–1767.
4. Parekkadan, B., Fletcher, A. L., Li, M., Tjota, M. Y., Bellemare-Pelletier, A., Milwid, J. M., et al. (2012). Aire controls mesenchymal stem cell-mediated suppression in chronic colitis. Molecular Therapy: The Journal of the American Society of Gene Therapy, 20(1), 178–186.
5. Corcione, A., Benvenuto, F., Ferretti, E., Giunti, D., Cappiello, V., Cazzanti, F., et al. (2006). Human mesenchymal stem cells modulate B-cell functions. Blood, 107(1), 367–372.
6. Di Nicola, M., Carlo-Stella, C., Magni, M., Milanesi, M., Longoni, P. D., Matteucci, P., et al. (2002). Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood, 99(10), 3838–3843.
7. English, K., Ryan, J. M., Tobin, L., Murphy, M. J., Barry, F. P., & Mahon, B. P. (2009). Cell contact, prostaglandin E(2) and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4 + CD25(High) forkhead box P3 + regulatory T cells. Clininical and Experimental Immunology, 156(1), 149–160.
8. Spaggiari, G. M., Capobianco, A., Abdelrazik, H., Becchetti, F., Mingari, M. C., & Moretta, L. (2008). Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2. Blood, 111(3), 1327–1333.
9. Spaggiari, G. M., Abdelrazik, H., Becchetti, F., & Moretta, L. (2009). MSCs inhibit monocyte-derived DC maturation and function by selectively interfering with the generation of immature DCs: central role of MSC-derived prostaglandin E2. Blood, 113(26), 6576–6583.
10. Aggarwal, S., & Pittenger, M. F. (2005). Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood, 105(4), 1815–1822.
11. Meisel, R., Zibert, A., Laryea, M., Gobel, U., Daubener, W., & Dilloo, D. (2004). Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood, 103(12), 4619–4621.
12. Liu, H., Lu, K., MacAry, P. A., Wong, K. L., Heng, A., Cao, T., et al. (2012). Soluble molecules are key in maintaining the immunomodulatory activity of murine mesenchymal stromal cells. Journal of Cell Science, 125(Pt 1), 200–208.
13. Sato, K., Ozaki, K., Oh, I., Meguro, A., Hatanaka, K., Nagai, T., et al. (2007). Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. Blood, 109(1), 228–234.
14. Bian, L., Guo, Z. K., Wang, H. X., Wang, J. S., Wang, H., Li, Q. F., et al. (2009). In vitro and in vivo immunosuppressive characteristics of hepatocyte growth factor-modified murine mesenchymal stem cells. In vivo, 23(1), 21–27.
15. Funk, C. D. (2001). Prostaglandins and leukotrienes: advances in eicosanoid biology. Science, 294(5548), 1871–1875.
16. Park, J. Y., Pillinger, M. H., & Abramson, S. B. (2006). Prostaglandin E2 synthesis and secretion: the role of PGE2 synthases. Clinical Immunology, 119(3), 229–240.
17. Hegyi, B., Kudlik, G., Monostori, E., & Uher, F. (2012). Activated T-cells and pro-inflammatory cytokines differentially regulate prostaglandin E2 secretion by mesenchymal stem cells. Biochemical and Biophysical Research Communications, 419(2), 215–220.
18. Chen, K., Wang, D., Du, W. T., Han, Z. B., Ren, H., et al. (2010). Human umbilical cord mesenchymal stem cells hUC-MSCs exert immunosuppressive activities through a PGE2-dependent mechanism. Clinical Immunology, 135(3), 448–458.
19. Lee, B. C., Kim, H. S., Shin, T. H., Kang, I., Lee, J. Y., Kim, J. J., et al. (2016). PGE2 maintains self-renewal of human adult stem cells via EP2-mediated autocrine signaling and its production is regulated by cell-to-cell contact. Scientific Reports, 6, 26298.
20. Hermankova, B., Zajicova, A., Javorkova, E., Chudickova, M., Trosan, P., Hajkova, M., et al. (2016). Suppression of IL-10 production by activated B cells via a cell contact-dependent cyclooxygenase-2 pathway upregulated in IFN-gamma-treated mesenchymal stem cells. Immunobiology, 221(2), 129–136.
21. Yu, K. R., Lee, J. Y., Kim, H. S., Hong, I. S., Choi, S. W., Seo, Y., et al. (2014). A p38 MAPK-mediated alteration of COX-2/PGE2 regulates immunomodulatory properties in human mesenchymal stem cell aging. PLoS One, 9(8), e102426.
22. Najar, M., Raicevic, G., Boufker, H. I., Fayyad Kazan, H., De Bruyn, C., Meuleman, N., et al. (2010). Mesenchymal stromal cells use PGE2 to modulate activation and proliferation of lymphocyte subsets: Combined comparison of adipose tissue, Wharton’s Jelly and bone marrow sources. Cellular Immunology, 264(2), 171–179.
23. Tian, Y., Wang, J., Wang, W., Ding, Y., Sun, Z., Zhang, Q., et al. (2016). Mesenchymal stem cells improve mouse non-heart-beating liver graft survival by inhibiting Kupffer cell apoptosis via TLR4-ERK1/2-Fas/FasL-caspase3 pathway regulation. Stem Cell Research & Therapy, 7(1), 157.
24. Baratelli, F., Lin, Y., Zhu, L., Yang, S. C., Heuzé-Vourc’h, N., Zeng, G., et al. (2005). Prostaglandin E2 induces FOXP3 gene expression and T regulatory cell function in human CD4 + T cells. Journal of Immunology, 175(3), 1483–1490.
25. Wang, Y., Han, Z. B., Song, Y. P., & Han, Z. C. (2012). Safety of mesenchymal stem cells for clinical application. Stem Cells International, 2012, 652034.
26. Hill, G. R., Crawford, J. M., Cooke, K. R., Brinson, Y. S., Pan, L., & Ferrara, J. L. (1997). Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines. Blood, 90(8), 3204–3213.
27. Markey, K. A., MacDonald, K. P., & Hill, G. R. (2014). The biology of graft-versus-host disease: experimental systems instructing clinical practice. Blood, 124(3), 354–362.
28. Dalrymple, N. A., & Mackow, E. R. (2014). Virus interactions with endothelial cell receptors: implications for viral pathogenesis. Current Opinion in Virology, 7, 134–140.
29. Krampera, M., Cosmi, L., Angeli, R., Pasini, A., Liotta, F., Andreini, A., et al. (2006). Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells, 24(2), 386–398.
30. Phinney, D. G. (2012). Functional heterogeneity of mesenchymal stem cells: implications for cell therapy. Journal of Cellular Biochemistry, 113(9), 2806–2812.
31. Kim, D. S., Lee, M. W., Yoo, K. H., Lee, T. H., Kim, H. J., Jang, I. K., et al. (2014). Gene expression profiles of human adipose tissue-derived mesenchymal stem cells are modified by cell culture density. PLoS One, 9(1), e83363.